bluuebunny/crossref_metadata_2025 huggingface dataset:
The efficacy of general anesthesia during pulmonary vein isolation compared with conscious sedation
Authors: Kikuchi M , Aizawa N , Furuya T , Tanno K
Published: October 2022

Background

Catheter ablation (RFA) is significantly more effective in terms of arrhythmia recurrence rate than antiarrhythmic medication. For the duration of the procedure, the patient needs to remain motionless on the operation table. General anesthesia (GA) is widely used during atrial fibrillation (AF) ablation in all over the world, however RFA of AF is performed under conscious sedation (CS) in the most centers in Japan.

It remains controversial whether cardiac anesthesiologists are best suited to manage anesthesia in the electrophysiology lab.

Objective

The aim of this study was to report the efficacy and safety of GA during AF ablation.

Methods

297 patients (67.3±11.7 years, 208 men, 128 paroxysmal, mean follow up 443 days±306) with AF undergoing RFA in our department from January 2018 to December 2021 were retrospectively analyzed. 113 assigned to the GA group, 184 patients to the CS group.

The primary efficacy end point was radiofrequency time, ablation index, force time integral. The secondary end points defined AF recurrence and the complications.

Result

There was no difference in the baseline characteristics between the two groups. There was no difference between groups in AF recurrence (22.1% vs. 14.1%, P=0.103) and complications.However, Patients in GA had shorter radiofrequency times (66.9±3.7 minute vs 79.0±2.9 minutes P=0.01)Ablation index (376±18.6 vs 371±22.6 P<0.05), Force time integral (136±22.3 vs 111.4±45.3).

Conclusion

General anesthesia is superior to conscious sedation with shorter radiofrequency times and higher than Force time integral, ablation index. Moreover, it is not inferior in regard to arrhythmia recurrence or complication rates of catheter ablation of atrial fibrillation.

Funding Acknowledgement

Type of funding sources: None.
Cryoballoon ablation in obese patients: it is worth it, let us work it
Authors: Boehmer A A , Rothe M , Nussbaum E , Dobre B C , Kaess B , Ehrlich J R
Published: October 2022

Background

Obesity is a major risk factor for atrial fibrillation (AF) development and of increasing prevalence in western countries. Safe and effective treatment methods for obese patients with AF are therefore important. Cryoballoon pulmonary vein isolation (CryoPVI) is a well-established therapy for symptomatic AF but data regarding obese patients are lacking.

Objective

To prospectively compare efficacy, safety and periprocedural parameters of CPVI in normal-weight and obese (Body-Mass-Index (BMI) ≥30kg/m2) patients.

Methods

We analyzed consecutive patients who underwent CryoPVI in a single-center cohort between 2018 and 2020. CryoPVI was performed in a standardized fashion. Follow-up was performed at 3, 6, 12, 18 and 24 months after CryoPVI. Endpoints were: symptomatic AF relapse for efficacy and bleeding, phrenic nerve injury, stroke or death for safety. Periprocedureal parameters were observed.

Results

We included 464 patients into the analysis, of these 331 patients had normal BMI (mean BMI 25.5±2.8 kg/m2, age 70±10 years, CHA2DS2-VASc 2.7±1.5, 56% male) while 133 patients (28.7%) suffered from obesity (mean BMI 33.2 kg/m2, age 67±9 years, CHA2DS2-VASc 2.7±1.4, 55% male). After 24 months freedom from AF relapse was similar for normal-weight and obese patients (58.8% vs. 61%, P=0.78, Figure 1A). Primary safety end point occurred in form of pericardial effusion or phrenic nerve injury in five patients with normal BMI (1.5%) and none obesity group. No deaths or strokes were observed in either group. Compared with control left-atrial dwell time (39.7±14.6 min vs. 44.8±18.7 min, P=0.002, fluoroscopy time (7.3±3.6 min vs. 8.3±4.1 min, P=0.013), contrast dye use (64.6±34.3 ml vs. 74.5±39.5 ml, P=0.009), and radiation dose (224.8±164.2 cGy·cm2 vs. 533.3±655.6 cGy·cm2, P<0.001) were significantly higher in obese patients (Figure 1B–E).

Conclusion

CryoPVI is safe and effective in obese patients but achievement of PVI is associated with longer procedure times, higher radiation exposure and contrast dye use.

Funding Acknowledgement

Type of funding sources: None.
Esophageal cooling during ablation of persistent atrial fibrillation is associated with improved freedom from arrhythmia at one-year follow up
Authors: Joseph C , Nazari J , Zagrodzky J , Sherman J , Zagrodzky W , Bailey S , Ro A , Fisher W , Metzl M
Published: October 2022

Background

Various factors influence successful freedom from atrial arrhythmia after pulmonary vein isolation (PVI) with radiofrequency (RF) ablation for the treatment of atrial fibrillation (AF). Lesion transmurality and continuity (as measured by the Continuity Index) are two important factors, and these can be worsened by pauses in RF energy application due to esophageal overheating. Proactive esophageal cooling precludes the need for premature cessation of power, avoiding partially-formed lesions and the need to “hop-scotch” in the left atrium. The resulting improvement in lesion continuity may improve long-term freedom from atrial arrhythmia after PVI, particularly in patients with persistent AF, where more posterior wall ablation is often necessary.

Purpose

Determine differences in freedom from arrhythmia at one year between patients receiving LET monitoring and those receiving esophageal cooling during PVI for persistent AF.

Methods

We reviewed data from two healthcare systems for patient rhythm status at one-year follow up after PVI for the treatment of persistent or long-standing persistent AF. We then determined Kaplan-Meier estimates of freedom from arrhythmia (AF, atrial flutter, and atrial tachycardia), and compared these between patients receiving esophageal cooling and those treated with traditional LET monitoring.

Results

A total of 252 patients received PVI for persistent or long-standing persistent AF and had data available for review. Of these, 148 received LET monitoring (with either a single or multi-sensor temperature probe), and 104 received active cooling with a dedicated esophageal cooling device. Mean age and gender for each group was similar (67.2, range 21 to 88 years, 36% female for LET monitoring, and 67.8, range 32 to 89 years, 30% female for esophageal cooling). KM estimates for freedom from AF at the one-year follow-up were 44.2% for LET monitored patients and 79.3% for actively cooled patients (P=0.01).

Conclusions

Freedom from atrial arrhythmia at one-year after PVI for persistent AF is associated with significant improvement when using active esophageal cooling rather than LET monitoring.

Funding Acknowledgement

Type of funding sources: Private company. Main funding source(s): Attune Medical
The left atrial low-voltage area and persistent atrial fibrillation treated with pulmonary vein isolation alone
Authors: Kwon S , Choi E K , Lee S R , Ahn H J , Oh S
Published: October 2022

Background

There are limited data regarding the association between the burden of the left atrial low-voltage area (LVA) and the outcome of pulmonary vein isolation (PVI) alone in persistent atrial fibrillation (PeAF).

Purpose

The study aimed to investigate the impact of the burden of LVA on the patients with PeAF treated with PVI alone.

Methods

Using a retrospective cohort of PeAF patients who underwent PVI alone, both clinical and the left atrial voltage mapping data were reviewed. LVA was defined as an area of ≤0.5 mV (bipolar) when mapped during sinus rhythm and ≤0.2 mV during AF. The high burden of LVA was defined as a case when the LVA constitutes ≥10% of the total left atrial body area. The patients were categorized into either the high or low burden groups. The recurrence of any atrial tachyarrhythmia was followed up, and multivariable Cox's regression analysis was performed.

Results

A total of 50 and 25 patients were investigated for the low burden (LVA<10%) and high burden (LVA≥10%) groups, respectively. Compared to the low burden group, the high burden group had a significantly less male proportion (56.0% versus 78.0%), a higher CHA2DS2-VASc score (median 3 versus 2), more chronic kidney disease (16.0% versus 2.0%), and a higher burden of LVA (20±11% versus 5±3%). During the median follow-up of 9.5 (6.2–16.2)months, there were 30.0% and 48.0% ofrecurrences for the low and high burden groups, respectively. Compared to the low burden group, the high burden group was associated with higher risks of both early and late recurrences (HR [95% CI] =2.67 [1.15–6.18] and 2.08 [1.03–4.20], respectively) (Figure 1). The best cut-off of LVA to predict 2-year recurrence was 10.1% (Figure 2).

Conclusion

The high burden of LVA was significantly associated with an increased risk of recurrence among PeAF patients treated with PVI alone. Tailored ablation in addition to PVI would be needed to improve outcomes in patients with PeAF having a high burden of LVA.

Funding Acknowledgement

Type of funding sources: None.
Recurrences after stereotactic arrhythmia radioablation for refractory ventricular tachycardia
Authors: Herrera Siklody C , Schiappacasse L , Jumeau R , Le Bloa M , Ozsahin M , Teres Castillo C , Moeckli R , Porretta A P , Pascale P , Domenichini G , Bourhis J , Pruvot E
Published: October 2022

Introduction

Stereotactic arrhythmia radioablation (STAR) has been recently introduced for the management of ventricular tachycardia (VT) refractory to antiarrhythmic drugs (AADs) and catheter ablation (CA). VT recurrences were recently reported after STAR but the mechanisms remain poorly known.

Purpose

We analyzed VT recurrences after STAR for refractory VT in order to assess the characteristics and delivered dose at sites of VT relapse.

Methods

From 09.2017 to 01.2020, 12 consecutive patients (pts) (66±8y, LVEF 40±14%) suffering from refractory VT were enrolled. The underlying cardiopathy was ischemic in 3, inflammatory in 3 and idiopathic in 6 pts. Nine (75%) out of 12 pts had a history of at least 1 electrical storm. Before STAR, an invasive electro-anatomical mapping (Carto3) of the VT substrate (VT-sub) was performed. A mean dose of 22±2Gy was delivered to the VT-sub using the Cyberknife® system.

Results

The ablation volume was 24±7cc and involved the basal interventricular septum (IVS) in 10 (83%) pts. During the first 6 months after STAR, VT burden decreased by 93% (mean value, from 640 to 46 VT/semester). After a median follow-up of 32±11 months, 10/12 (83%) developed ≥1 recurrence as a sustained VT and underwent a redo CA. Two (17%) pts presented 2 distinct VT recurrences from clearly different areas. VT recurrence was located at the border zone (BZ) of the treated VT-sub in 6 (50%) cases, involved both the BZ and a larger substrate in 2 (17%) cases, and occurred remote from the VT-sub in 4 (33%) cases (see Table 1). The dose delivered at sites of VT recurrence was 8.4±8.6 Gy with a large heterogeneity ranging from 0.11 to 28.37 Gy, for some pts due to dose constraints near critical structures (coronary arteries). Voltage mapping showed a small but significant reduction in both unipolar and bipolar EGM voltage in the irradiated area after STAR (before vs after, Bipolar: 1.8±1.2 vs 1.1±1.2 mV and Unipolar: 4.4±2.0 vs 3.4±2.3 mV, p=0.02 and 0.01 respectively). Importantly no pts developed a high-grade AV block after STAR despite IVS irradiation.

Conclusion

STAR appears to be an efficient tool for the management of refractory VT, leading to a strong VT burden reduction and no new high-grade AV block. Recurrences were nevertheless common, often at the border zone of the irradiated volume.

Funding Acknowledgement

Type of funding sources: Public hospital(s). Main funding source(s): CHUV
Novel electrogram featurization reveals a spectrum of response to ablation from atrial tachycardia to types of atrial fibrillation
Authors: Ganesan P , Rogers A J , Deb B , Feng R , Ruiperez-Campillo S , Tjong F V , Bhatia N , Clopton P , Rappel W J , Narayan S M
Published: October 2022

Background

Although atrial tachycardia (AT) may interconvert with fibrillation (AF) in many patients, it is undefined if this represents a pathophysiological spectrum of organization, or whether it indicates that AF will respond better to ablation.

Objective

To test the hypothesis that the spatial area within which electrograms (EGMs) repeat in synchronized fashion over time indicates a spectrum from AT, in which areas span the entire atria, to AF, in which areas are limited. We further hypothesized that repetitive areas would be larger in AF patients with acute termination than in those with poor response to ablation.

Methods

We studied N=234 patients (47% women, 64±10Y), of whom (i) N=10 had AT, (ii) N=120 had AF that terminated with ablation (“Term”), (ii) N=104 had AF that did not terminate (“Non-term”). All patients had global left atrial mapping by 64 pole baskets (Abbott, IL). Spatial areas of repetitive activity (REACT) were calculated by correlating unipolar EGMs in 2x2 grids for 4 sec, repeated for the entire atria (Figure 1A, B). We quantified global organization by averaging the REACT map for each patient.

Results

Figure 1C shows progressively decreasing areas of repetitive EGM from AT to AF Term to AF Non-term (p<0.001, ANOVA). Figure 1D shows a case of AT in a 71 YO male and global REACT >0.90, a case of AF REACT 0.45 in a 65 YO male with termination by ablation, and a case of AF with REACT 0.19 in an 85 YO male that did not terminate. Further, ROC analysis of REACT analysis in AF cases predicted termination with an AUC of 0.71.

Conclusion

Spatial areas of repeating electrogram shapes indicates a spectrum from AT to AF with good and AF with poor acute response to ablation. Future studies should investigate whether REACT areas can be identified non-invasively, such as by body surface ECG, to guide ablation or prognosis.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): US National Institutes of Health
Machine learned clusters explain heterogeneity in outcomes from map-guided ablation of Atrial Fibrillation results from the large PROspective STanford AF Registry (ProSTAR)
Authors: Deb B , Rogers A J , Bhatia N K , Baykaner T , Turakhia M , Clopton P L , Chang H J , Brodt C , Narayan S M , Wang P J , Viswanathan M N
Published: October 2022

Background

Several mapping systems are being introduced to guide atrial fibrillation (AF) ablation to patient-specific regions of interest. However, results have been extremely heterogeneous between studies, ranging from very poor to very promising. It is unknown if this reflects specific patient characteristics or procedural factors because most prior series were middle sized (N∼30–100 patients).

Purpose

To study 1 year and 3 year very long-term outcomes from map guided AF-driver ablation in a large patient registry with multiple operators, to identify clinical and procedural features influencing outcomes. In real-world AF patients with diverse comorbidities, we applied a consistent patient-tailored AF mapping and ablation strategy, monitored outcomes carefully and applied statistical and unsupervised machine learning approaches to identify features of success and failure.

Method

We studied 632 consecutive patients (65±10 y, 178 F) undergoing ablation for drug-refractory AF. 59.7% had persistent AF, and 29.9% had prior unsuccessful ablation (median 1 procedure). All patients underwent pulmonary vein isolation (PVI), followed by ablation of AF regions of interest mapped from 64 pole baskets (RhythmView, Abbott, IL), by 11 operators. Patients were followed using ambulatory ECG monitors quarterly for one year, and at the time of symptoms for 3 years.

Results

Fig. 1A shows overall freedom from AF at 1-year of 77.5% (95% CI: 74.2%, 80.9%) and at 3 years of 55.5% (95% CI: 51.2%, 60.1%). Freedom from AF/AT at 1-year was 70.1% (95% CI: 66.5%, 73.8%), and at 3 years was 48.6% (95% CI: 44.3%, 53.3%). Success was higher in patients with procedural termination, first ablation versus prior unsuccessful procedures, for paroxysmal AF than non-paroxysmal AF (1 year: AT/AF freedom 74.9% versus 66.7%, p=0.006), and smaller left atrium. Three clusters (Fig 1B) were identified comprising CHA2DS2VASc score, enlarged LA, prior failed case, presenting rhythm and termination during the procedure (Table 2). At 1 year, freedom from AT/AF was 77.8% (95% CI: 72.2%, 82.1%) for cluster 3 and 56.2% (95% CI: 48.3%, 65.4%) for cluster 1 (Fig. 1B).

Conclusion

In our large registry of N=632 patients undergoing AF-map guided ablations, machine learned clusters identified cohorts with success of 56.2 to 77.8% at 1 year. Future studies should identify if lower success represents technical challenges, such as difficulties in mapping very large atria, or more difficult to treat mechanisms. These results may inform patient inclusion and ablation strategy in upcoming AF treatment trials.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National budget only - NIH, R01 HL149134, R01HL83359
Edoxaban in dialysis: a 4-year follow-up in a single center experience
Authors: Fazio G , Schiro P , Milana G
Published: October 2022

Background

Patients with atrial fibrillation (AF) and advanced chronic kidney disease (CKD) are at high risk of adverse events and are complicated to manage. There is little evidence on the effects of non-vitamin K oral anticoagulants in patients with severe CKD. Preliminary data in patients taking edoxaban whose creatinine clearance fell below 30 mL/min showed a low risk of stroke and major bleeding. The aim of our study is to test the safety of edoxaban 30 mg/day in patients with severe renal impairment with an estimated glomerular filtration rate (eGFR) <15 mL/min in dialisys.

Methods

We analyzed retrospective data from 46 patients who had documented AF with severe renal impairment (eGFR <15 mL/min). The follow-up, characterized by clinical examination and blood analysis, was performed every 6 months. The main endpoint was the incidence of major bleedings or clinically relevant non-major (CRNM) bleedings or thromboembolic events.

Results

All patients included were treated with Edoxaban for atrial fibrillation.

At the time of the data collection, the mean follow-up in valvular patients was 24±2 months. There were no major bleedings, strokes, transitory ischemic event, systemic embolisms, or cardiovascular deaths were been reported. 3 (12.5%) cases of minor bleeding was reported. The complication rate of the patients in dialysis are the same than the atrial fibrillation population without any statistical differences (1.39% vs 1,37%, p: 0.96).

Conclusion

The use of Edoxaban in dialysis and atrial fibrillation seems safe and effective.

Funding Acknowledgement

Type of funding sources: None.
Impact of diabetes and glucose-lowering therapy on post-operative atrial fibrillation after cardiac surgery: secondary analysis of the SEARCH-AF CardioLink-1 randomized clinical trial
Authors: Pandey A , Hibino M , Ha A , Quan A , Verma A , Bisleri A , Mazer C D , Verma S
Published: October 2022

Background

Diabetes mellitus is an important risk factor for atrial fibrillation (AF) and is associated with an increased risk of complications for patients with AF. The impact of diabetes on post-operative AF after cardiac surgery is not well-defined.

Purpose

We sought to characterize the effect of diabetes, insulin, and oral hypoglycemic agents on the incidence of post-operative atrial fibrillation (POAF) after cardiac surgery. Accordingly, we conducted a secondary analysis of the Post-Surgical Enhanced Monitoring for Cardiac Arrhythmias and Atrial Fibrillation (SEARCH-AF) CardioLink-1 randomized trial.

Methods

In the SEARCH-AF trial, 336 patients with risk factors for stroke (CHA2DS2-VASc score ≥2) and no history of preoperative AF were randomized to usual care or continuous cardiac rhythm monitoring for 30 days after discharge from cardiac surgery with a wearable, patched-based device. The primary outcome was occurrence of cumulative atrial fibrillation/flutter (AF/AFL) lasting for ≥6 minutes detected by continuous monitoring or AF/AFL documented by a 12-lead electrocardiogram within 30 days of randomization. We assessed the association between diabetes and occurrence of post-operative AF. In addition, we examined the association between POAF and glucose-lowering therapy among patients with diabetes.

Results

Among the 176 (52%) patients with diabetes in the study cohort, 80 (45%) patients were treated with at least 1 oral hypoglycemic agent and 44 (25%) patients were treated with insulin. The incidence of POAF occurring within 30 days after discharge from surgery was similar between patients with or without diabetes (cumulative incidence: 10.8% vs. 10.0%, log-rank p=0.77). Among patients with diabetes, the incidence of POAF was highest in those who were not treated with glucose-lowering therapy (17.3%) when compared with those treated with oral hypoglycemic agents (10.0%) or insulin (4.5%) (log-rank ptrend=0.045 among the 3 groups). In an exploratory analysis, we observed a trend suggesting a lower incidence of POAF among cardiac surgical patients who were treated with SGLT-2 inhibitors (log-rank ptrend=0.084).

Conclusion

The incidence of POAF occurring after discharge from cardiac surgery is equally high among patients with or without diabetes. Our results suggest a potential association between specific glucose-lowering therapies and risk of POAF after cardiac surgery, meriting further investigations.

Funding Acknowledgement

Type of funding sources: Other. Main funding source(s): Heart and Stroke Foundation of Canada
The Mueller maneuver attenuates left atrial phasic volumes and myocardial strain in healthy younger adults
Authors: Wright S P , Dawkins T G , Harper M I , Shave R , Eves N D
Published: October 2022

Background

Negative intrathoracic pressure swings alter cardiac loading conditions, which may impact left atrial hemodynamic function and augment atrial stress. If such changes occur and are repeated chronically, they may contribute to the marked atrial remodeling seen in states associated with forceful inspiratory efforts such as endurance training or obstructive sleep apnea.

Purpose

We studied the acute effects of static inspiratory efforts on left atrial chamber function, myocardial mechanics, and diastolic function.

Methods

We included healthy adults (10M/7F, 24±4 years) and used Mueller maneuvers to reduce intrathoracic pressure to a −30 cmH2O target for 15 seconds. Over 6 repeated trials, we used echocardiography to acquire left atrial and ventricular focused 2D images, and mitral Doppler inflow and annular tissue velocity spectra. Images were analyzed offline to determine left ventricular volumes, tissue relaxation velocities, trans-mitral filling velocities, and phasic left atrial volumes and myocardial strain using speckle-tracking imaging. Repeated measures were made at Baseline, within the last 5 seconds of the Mueller maneuver, and within the first 5 seconds after release, with 3–5 cardiac cycles averaged per measurement.

Results

Compared to Baseline, hemodynamic changes occurred during the late phase of the Mueller maneuver and immediately after release. Left ventricular stroke volume decreased by −10±4 mL (p<0.05) then returned to baseline upon release; this was associated with a −11±9 mL (p<0.05) reduction in end-diastolic volume. Left ventricular early diastolic filling attenuated, reflected by decreases in mitral annular relaxation velocity (−2±2 cm/s, p<0.05), E-wave filling velocity (−13±14 cm/s, p<0.05), and left atrial passive emptying volume (−5±5 mL, p<0.05), each normalizing upon release. Left atrial maximal volume decreased (−5±5 mL, p<0.05) during the Mueller maneuver, but increased relative to baseline (+4±5 mL, p=0.049) following release, while left atrial peak positive longitudinal strain decreased (−6±6%, p<0.05) and normalized upon release.

Conclusions

Attenuated left atrial and in turn ventricular filling may contribute to acute stroke volume reduction during forceful inspiratory efforts. Rapid changes in left atrial chamber volumes and myocardial strain with the release of forceful inspiratory efforts may reflect acute left atrial stress.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Natural Sciences and Engineering Research Council Discovery Grant
Elevated thrombin generation levels in the left atrial appendage in patients with atrial fibrillation
Authors: Elias A , Khoury Y , Shehadeh F , Ron G , Boulos M , Zukermann R , Elias M , Gepstein L , Suleiman M
Published: October 2022

Introduction

Atrial Fibrillation (AF) is the most common sustained arrhythmia. Thrombus formation in the left atrial appendage (LAA) increases the risk for stroke and systemic embolism in AF patients. The proposed mechanisms for thrombus formation in the LAA are stasis, endothelial dysfunction and local hypercoagulability. The aim of this study was to compare thrombin generation potential in various heart chambers among AF patients.

Material and methods

A prospective cross-sectional study of 47 patients with AF undergoing pulmonary vein isolation (PVI). Blood samples from the femoral vein (FV), right atrium (RA), left atrium (LA) and LAA were collected during the PVI procedures. The Samples were collected before heparin administration. Thrombin generation was assessed by the calibrated automated thrombogram (CAT).

Results

A total of 47 patients (36.2% female, mean age 58.7±13, 59.6% with CHADS-VASc ≥2) were enrolled into the study. The mean endogenous thrombin potentials (ETP) were 1580±558, 1433±540, 1141±611 and 1487±760 in the FV, RA, LA and LAA, respectively (P<0.05). The mean thrombin peak heights were 244±124, 199±102, 139±94 and 195±129 in the FV, RA, LA and LAA, respectively (P<0.05).

A post-hoc pairwise comparison demonstrated elevated thrombin generation in the LAA compared to the LA (P=0.014). Furthermore, LA thrombin generation levels were significantly lower from the FV and RA (P<0.05).

Conclusion

In patients with AF, the LAA has increased thrombotic potential compared to the LA. These findings might explain why the LAA is more predisposed to thrombus formation than the LA.

Funding Acknowledgement

Type of funding sources: None.
Bone morphogenetic protein 10 as predictor for adverse outcomes in patients with atrial fibrillation
Authors: Hennings E , Blum S , Aeschbacher S , Coslovsky M , Knecht S , Paladini R E , Krisai P , Kastner P , Ziegler A , Mueller C , Zuern C S , Bonati L , Conen D , Kuehne M , Osswald S
Published: October 2022

Background

Patients with atrial fibrillation (AF) face an increased risk of death and major adverse cardiovascular events (MACE). Bone morphogenetic protein 10 (BMP10) is a novel atrial-specific biomarker, but data about its prognostic value in AF patients are lacking.

Purpose

We aimed to assess the predictive value of BMP10 for death and MACE in AF patients in comparison to N-terminal prohormone of B-type natriuretic peptide (NT-proBNP).

Methods

Baseline concentrations of BMP10 and NT-proBNP were measured in stable patients with AF enrolled in Swiss-AF, a prospective multicenter observational cohort study. Primary outcomes were all-cause death and MACE (composite of heart failure hospitalization, cardiovascular death, stroke, systemic embolism, myocardial infarction). Measures of discriminative power were used to compare multivariable Cox proportional hazard models using the different biomarkers.

Results

A total of 2219 AF patients were included with a median follow-up of 4.3 years (IQR 3.9, 5.1). Mean age was 73±9 years and 27% were women. Incidence rate per 100 patient-years of all-cause death and MACE increased across BMP10 quartiles (Figure 1). In the multivariable adjusted Cox proportional hazard model, the hazard ratio (HR) and 95% confidence interval (CI) of BMP10 was 1.60 (1.37; 1.87) to predict all-cause death, and 1.54 (1.35; 1.76) to predict MACE. For all-cause death, the C-index (95% CI) was 0.783 (0.763; 0.809) for BMP10, 0.784 (0.765; 0.810) for NT-proBNP, and 0.789 (0.771; 0.815) for both biomarkers combined. For MACE, the C-index (95% CI) was 0.732 (0.715; 0.754) for BMP10, 0.747 (0.731; 0.768) for NT-proBNP, and 0.750 (0.734; 0.771) for both biomarkers combined. When grouping patients according to clinical used NT-proBNP categories (<300, 300–900, >900 ng/l), higher incidence rates and adjusted HRs were observed for the primary outcomes in patients with high BMP10 in the categories of low NT-proBNP (all-cause death aHR 2.28 [1.15; 4.52], MACE aHR 1.88 [1.07; 3.28]) and high NT-proBNP (all-cause death aHR 1.61 [1.14; 2.26], MACE aHR 1.38 [1.07; 1.80]) (Figure 2).

Conclusion

The novel atrial-specific biomarker BMP10 strongly predicts all-cause death and MACE in patients with AF. BMP10 provides additional prognostic information in low- and high-risk patients according to NT-proBNP stratification.

Funding Acknowledgement

Type of funding sources: Foundation. Main funding source(s): Swiss National Science Foundation, Swiss Heart Foundation
Prognosis of atrial fibrillation with or without comorbidities. Analysis of younger adults from a nationwide database
Authors: Cottin Y , Mertz V , Bentounes S A , Pastier Debeaumarche J , Didier R , Herbert J , Zeller M , Lip G Y H , Fauchier L
Published: October 2022

Background

“Lone AF” may be defined as AF in younger adults (age <60 years) and lack of obvious associated CV or extra CV conditions. However, current ESC guidelines indicate that the term of “Lone AF” is potentially confusing and should be abandoned because a cause may be present in every patient. In addition, studies on prognosis of “Lone AF” are inconsistent, likely as the result of the heterogeneity in definitions, comorbidities, study population and duration of follow-up. We aimed to assess the prognosis of patients with AF with or without cardiac or extra cardiac concomitant conditions.

Participants and methods

From the French administrative hospital-discharge PMSI database (Programme de Médicalisation des Systèmes d'Information) covering hospital care and representative of the whole French population, all consecutive patients with AF diagnosis hospitalized between 2011 and 2020 were identified. Patients were classified into four groups: 1) >60 yo; 2) with known cardiac disease (KCD group); 3) with extra cardiac comorbidities (ECC); and 4) AF without KCD or ECC (“Lone AF”).

Results

Altogether 2,435,541 patients were identified, from which 2203,702 patients aged >60 years and 231,839 patients aged <60 years [with KCD (55.2%), with ECC (14.7%) and with “Lone AF” (30.1%)]. During follow-up the incidences of all-cause and CV deaths were 13.7%, 5.7%, 6.2% and 2.3%, and 4.2%, 1.7%, 0.8% and 0.3% in the older than 60 yo group, KCD group, ECC group and “Lone AF” AF group, respectively. In the age and sex-adjusted analysis (patients <60 yo), patients with AF and KCD had worse outcomes than patients with “Lone AF” for all major cardiac events (see figures).

Conclusion

There are three distinct prognostic criteria based on the presence or not of HD or extra cardiac concomitant comorbidities. Patients in the so-called “Lone AF” group remain severe in terms of CV events but still with a lower incidence than the patient with associated KCD or ECC. The presences of KCD or ECC make it possible to distinguish a profile in terms of events that are very different from the patients.

Funding Acknowledgement

Type of funding sources: None.
Characteristics of incident atrial fibrillation patients – a nationwide register-based study with information from primary-, secondary- and tertiary care
Authors: Kouki E , Salmela B , Haukka J , Halminen O , Karlsson E , Mustonen P , Putaala J , Linna M , Aro A , Hartikainen J , Airaksinen K E J , Lehto M
Published: October 2022

Introduction

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with a current prevalence of 4.1% in Finland. Many of the comorbidities associated with AF are known risk factors for the arrhythmia and vice versa, as well as contributors to the risk of stroke and other AF related adverse events. A generally used evaluation method for the risk of stroke is the clinical risk factor -based CHA2DS2-VASc score, but other thromboembolic risk factors also exist.

Purpose

To better understand current AF population, this study describes characteristics, comorbidities, medication, and laboratory values of Finnish AF patients at the time of first AF diagnosis.

Methods

The Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) study is a nationwide register-based cohort study in which AF patient data has been linked from several Finnish health care- and national registers, with information from primary-, secondary-, and tertiary care. This substudy consists of patients over 20 years old with available laboratory data and an incident AF diagnosis (ICD-10 I48) between 1/1/2010–31/12/2018 in any of the used registers.

Results

Within the study period 143,455 patients with a new AF were registered. The mean age at time of diagnosis was 69.1 years for men and 76.3 years for women. The mean CHA2DS2-VASc score when entering the cohort was 3.48 (SD 1.88), and 84.9% of the cohort had at least one of the comorbidities included in the CHA2DS2-VASc score. The most prevalent comorbidities and medications of the cohort are shown in the figure, and a more comprehensive look is presented in the table. The medications listed have been in use during the year before cohort entry.

Conclusion

Atrial fibrillation does not come alone. Almost all patients diagnosed with AF have previous comorbidities and medications. Future analysis will provide information on how these evolve after AF diagnosis and elucidate their association with different endpoints.

Funding Acknowledgement

Type of funding sources: Public hospital(s). Main funding source(s): Helsinki and Uusimaa Hospital District
Paradoxical association between lipid levels and incident atrial fibrillation according to statin usage
Authors: Ahn H J , Lee S R , Choi E K , Lee S W , Han K D , Kwon S , Oh S , Gregory L I P
Published: October 2022

Background

In epidemiology studies, a higher level of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) is associated with a lower risk of atrial fibrillation (AF). Statin use might exert possible confounding effects in the paradoxical relationship; however, the inverse link between AF and cholesterol level that distinguishes statin users from non-users has not been evaluated.

Objective

We investigated the epidemiological relationships of TC–AF and LDL-C–AF in statin users and non-users, respectively.

Methods

From the Korean National Health Insurance Service database, we included 9,778,014 adults who underwent a health examination in 2009 and had no prior AF history. The levels of TC and LCL-C at the health exam were categorized in quartile (Q) and decile (D) values of the total study population. The study population was grouped into statin users and non-users, and TC–AF and LDL-C–AF relationships were evaluated.

Results

867,336 (8.9%) were on statin use among the total population. Statin users showed higher TC level (208.4±55.6 vs. 194.1±39.5 mg/dL, p<0.001) and LDL-C level (123.0±102.2 vs. 121.3±226.3, p<0.001) compared to non-users. Inverse associations of TC–AF and LCL-C–AF were observed; higher levels of TC and LDL-C were associated with a lower risk of AF. The hazard ratios (HR) and 95% confidence intervals (CI) were 0.797 (0.786–0.809) for the highest quartile of TC (Q4, TC ≥218) and 0.832 (0.82–0.843) for the highest quartile of LDL-C (Q4, LDL-C ≥135) when adjusted by age, sex, lifestyle behaviors, comorbidities, and low-income status. Statin users exhibited higher AF incidence rate than non-statin users, but the association in statin users generally tracked that seen among non-statin users demonstrating similar HR in Q4 of TC [0.812 (0.790–0.835) for statin users and 0.812 (0.798–0.826) for non-statin users] and LDL-C [0.842 (0.819–0.865) for statin users and 0.849 (0.835–0.863) for non-statin users].

Conclusion

The paradoxical relationship between lipid levels (TC and LDL-C) and incident AF remained consistent both in statin users and non-users. Further research is required to investigate an underlying mechanism for the cholesterol paradox of AF which still seems evident despite the pleiotropic effects of statin.

Funding Acknowledgement

Type of funding sources: None.
Prevalence of atrial fibrillation and feasibility of pulmonary vein isolation after patent foramen ovale closure
Authors: Fabbricatore D , Paolisso P P , Gallinoro E G , De Colle C D C , Valeriano C V , De Schouwer K D S , Geelen P G , Barbato E B , De Potter T D P
Published: October 2022

Background

Data about prevalence and the risk of atrial fibrillation, stroke, and need for pulmonary vein isolation (PVI) after device closure of a patent foramen ovale (PFO) are still lacking.

We aim to investigate the prevalence and the risk of atrial fibrillation after PFO closure and the feasibility of PVI in a PFO closure cohort compared to contemporary PVI without PFO closure.

Methods

Retrospective observational study of consecutive patients undergoing PFO closure enrolled from February 2013 to September 2020. Patients were divided into 3 groups: i) patients without AF before and after the procedure (n=132), ii) patients with paroxysmal AF prior to the procedure (n=21), iii) patients with documented AF after the procedure (n=13). All patients with AF occurrence were treated with adequate anticoagulation therapy according to the current ESC Guidelines. We compared the procedural data of these patients to a matched contemporary cohort without previous PFO closure undergoing PVI in our center. AF and stroke prevalence and PVI feasibility after PFO closure were assessed at follow up.

Results

One-hundred and sixty-six consecutive PFO closure patients were enrolled; the mean age was 54±13 years. Median follow-up was 3.5±2.5 years. During the study period, 21 patients had AF before or after the PFO closure (group 2) and 13 (7.8%) new onset AF (group 3). Stroke after the PFO closure occurred in 8 patients (4.8%), of which 4 in the group with new onset AF (30% of the group 3).

Among the 34 patients with AF, 10 patients (6%) underwent a PVI. Compared to a contemporary matched PVI cohort, total procedural times and fluoroscopy times were significantly higher in the patients with previous PFO closure (108±15 vs 75±29, p=0.002 and 3±1.5 vs 8±7, p<0.001). Similar rate of AF relapses (p=0.198) was observed between the two groups, with a trend for higher rate of complication (pericardial effusion) for the cohort with previous PFO closure (p=0.06).

Conclusion

This study shows that a more accurate screening and treatment of AF is needed in patients with cryptogenic stroke despite the presence of a PFO, possibly a bystander. In our study, 30% of patients with new onset AF after PFO closure, experienced a further stroke after the procedure. In case of AF, the indication for PVI should be considered prior to the PFO closure since it turns out to be more difficult in terms of procedural and fluoroscopy times and risks of complications after PFO closure.

Funding Acknowledgement

Type of funding sources: Public Institution(s).
Searching for underlying atrial fibrillation using artificial intelligence-assisted MRI images from ischemic stroke patients
Authors: Zhang Z , Lin K , Wang J , Ding L , Sun Y , Fu C , Qian D , Li J , Huang D
Published: October 2022

Background

Nearly 30% of ischemic strokes are attributed to atrial fibrillation (AF) related cardiac thromboembolism. This subset of strokes are associated with higher recurrence rate, morbidity and mortality. As a result, current recommendation suggests a cardiac monitoring of variable intensity and duration to search for unknown AF after a stroke so that optimal secondary prevention could be administered. Unfortunately, it is reported that 24h Holter ECG monitoring for underlying AF is completed routinely in only a minority of stroke centers, making a huge gap between AF detection rate in clinical practice and estimated actual data (2–3% vs 23–30%). So, it is obvious that paroxysmal AF remains undetected in a significant proportion of patients after a stroke and an early and effective identification approach of cardiac disturbances is needed.

Purpose

We aim to develop an innovative end-to-end artificial intelligence model to rapidly search for atrial fibrillation in post ischemic stroke patients using MRI imaging data.

Methods

489 patients diagnosed with ischemic stroke, 174 of which had a prior known history of AF or new AF detected by intensive ECG monitoring poststroke, from January 2018 to October 2021 were enrolled in this study. The MRI images obtained after their admission in the stroke unit were meticulously evaluated and acute ischemic stroke lesions on DWI sequences were segmented and confirmed by two senior neuroradiologists independently. These processed images were randomly split into training (n=315) and testing set (n=174) for the implementation and validation of our AI screening model. And the algorithm was based on the combination of radiomic features and semantic features extracted from convolutional neural network (CNN). The model performance was evaluated by accuracy, recall, precision, F-Measure and AUC. Also, heatmaps which indicate the attention mechanism of the model were generated for interpreting underlying patterns.

Results

The AUC of our model (COM) reached 0.8 (Figure 1A). Also, the algorithm yielded values for the accuracy, recall, precision and F-Measure of 70%, 92.5%, 63.8% and 75.5%, respectively, which showed satisfactory classification results. As to the interpretability of the AI model, we found that more “attention” was paid to the main lesions (Figure 1B) and radiomic features which indicated the minimum gray level intensity and the sphericity of the lesions (Figure 1C, D) were crucial to the classifier.

Conclusions

Our work revealed a potential correlation between brain ischemic lesion pattern on DWI images and underlying etiology of AF. Moreover, the AI model we developed may serve as a rapid screening tool for AF in clinical practice of stroke units.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National Natural Science Foundation of China
Impact of metabolic syndrome on the risk of ischemic stroke in non-anticoagulated atrial fibrillation patients having low CHA2DS2-VASc scores
Authors: Ahn H J , Choi E K , Lee S R , Lee S W , Han K D , Kwon S , Oh S , Gregory L I P
Published: October 2022

Background

Metabolic syndrome (MetS) predisposes to a thromboembolic state. However, conflicting results have been reported on whether MetS confers an increased risk of ischemic stroke in atrial fibrillation (AF), especially in patients with low CHA2DS2-VASc score who are not indicated for oral anticoagulant therapy.

Purpose

We investigated the risk of ischemic stroke according to the presence of MetS, the number of MetS components (metabolic burden), and the individual metabolic components in non-anticoagulated AF patients with low CHA2DS2-VASc score.

Methods

A total of 76,015 oral anticoagulant-naïve AF patients with low CHA2DS2-VASc score (0,1 in male and 1 in female) were included from the Korean National Health Insurance Service database. The status of MetS and individual metabolic components were evaluated based on health examination data within two years of AF diagnosis. We estimated the risk of ischemic stroke according to MetS, metabolic burden, and an individual component of MetS using Cox proportional-hazards models.

Results

The mean age was 49.8±11.1 years and 52,388 (68.9%) were male. The average CHA2DS2-VASc score was 0.7±0.5 and MetS was prevalent among 21,570 (28.4%) of the study population. During a mean follow-up of 5.1 years, ischemic stroke was developed in 1,395 (1.84%) patients. MetS was associated with a higher risk of ischemic stroke after adjustment for age, sex, lifestyle behaviors, low income, and cardiovascular comorbidities: adjusted hazard ratio (aHR) 1.19, 95% confidence interval (CI) 1.06–1.33, p=0.002. A positive linear correlation was observed between metabolic burden and ischemic stroke risk. Patients with five MetS components showed the highest aHR of 1.55 (95% CI 1.14–2.11, Figure 1 and Figure 2), whereas those with a single MetS component had a marginal risk of ischemic stroke (aHR 1.18, 95% CI 0.99–1.41). Among individual metabolic components, elevated blood pressure and increased waist circumference was significantly associated with an increased risk of ischemic stroke: aHR (95% CI), 1.45 (1.30–1.62), p<0.001, and 1.15 (1.03–1.30), p=0.016, respectively.

Conclusions

Among AF patients initially with CHA2DS2-VASc score 0 and 1 with no anticoagulation, the presence of MetS is associated with an increased risk of ischemic stroke. Given the linear incremental correlation between metabolic burden and ischemic stroke, special attention to the care of metabolic derangements is required in AF patients who are not indicated for anticoagulation.

Funding Acknowledgement

Type of funding sources: None.
Association between early rhythm control and the risk of dementia in patients with atrial fibrillation and prior history of stroke: a nationwide population-based study
Authors: Lee S R , Choi E K , Lee S W , Han K D , Oh S , Lip G Y H
Published: October 2022

Background

Patients with atrial fibrillation (AF) who experienced stroke before are at high risk for dementia. Although early rhythm control in patients with AF reduces the risk of stroke, there is a lack of evidence on whether early rhythm control reduces the risk of developing dementia in patients with new-onset AF and a history of prior stroke.

Purpose

To compare the risk of dementia between early rhythm control therapy and usual care in patients with new-onset AF and a history of prior stroke

Methods

Using the Korean nationwide claims database, we identified patients who were newly diagnosed as AF and had a history of prior stroke. Patients with prevalent dementia were excluded. Patients who received rhythm control therapy, including antiarrhythmic drug, direct current cardioversion, or AF catheter ablation, within 1 year after incident AF were defined as the early rhythm control group, otherwise as the usual care group. The inverse probability of treatment weighting method was used to balance baseline characteristics between the two groups. The incidence of all dementia, Alzheimer dementia, and vascular dementia were evaluated during follow-up.

Results

A total of 41,370 patients were included (mean age, 70±11 years; mean CHA2DS2-VASc score 5.3±1.6; 43% female); 10,213 were in the early rhythm control group and 31,157 in the usual care group. All patients received oral anticoagulants. During a median 2.7 years of follow-up, 6414 patients developed incident dementia (incidence rate, 4.9 per 100 person-years). Compared to usual care, early rhythm control was associated with lower risks of all dementia, Alzheimer dementia, and vascular dementia (weighted hazard ratio [95% confidence interval], 0.825 [0.776–0.876], 0.831 [0.774–0.893], and 0.800 [0.702–0.913], respectively, all p<0.001) (Figure 1). The beneficial effect of early rhythm control on the risk of dementia were consistent regardless of the characteristics of prior stroke, for example, recent stroke within 6-month from their enrollment, disabling stroke that required continuous rehabilitation therapy, and severe stroke causing intensive care unit admission.

Conclusion

Early rhythm control within 1 year after AF diagnosis might be beneficial to prevent dementia in patients with incident AF and a history of stroke. To prevent progression of further cognitive dysfunction, early rhythm control should be considered in these patients.

Funding Acknowledgement

Type of funding sources: None.